Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 11;24(6):5377.
doi: 10.3390/ijms24065377.

Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research

Rafał Skopek  1 , Małgorzata Palusińska  1 , Katarzyna Kaczor-Keller  1 , Rafał Pingwara  2 , Anna Papierniak-Wyglądała  3 , Tino Schenk  4   5 , Sławomir Lewicki  6   7 , Artur Zelent  1 , Łukasz Szymański  1
Affiliations
Review

Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research

Rafał Skopek et al. Int J Mol Sci. .

Abstract

Immortalized cell lines are widely used in vitro tools in oncology and hematology research. While these cell lines represent artificial systems and may accumulate genetic aberrations with each passage, they are still considered valuable models for pilot, preliminary, and screening studies. Despite their limitations, cell lines are cost-effective and provide repeatable and comparable results. Choosing the appropriate cell line for acute myeloid leukemia (AML) research is crucial for obtaining reliable and relevant results. Several factors should be considered when selecting a cell line for AML research, such as specific markers and genetic abnormalities associated with different subtypes of AML. It is also essential to evaluate the karyotype and mutational profile of the cell line, as these can influence the behavior and response to the treatment of the cells. In this review, we evaluate immortalized AML cell lines and discuss the issues surrounding them concerning the revised World Health Organization and the French-American-British classifications.

Keywords: AML cell lines; AML subtypes; CD markers; FAB; WHO; genetic rearrangements.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic diagram representing the AML diagnosis process based on the FAB classification and the samples’ immunophenotypic, cytochemical, and morphological properties.
Figure 2
Figure 2
AML classification based on the fifth edition of the WHO classification [5].
Figure 3
Figure 3
Simplified diagram of the procedure for the establishment of human leukemic cell lines. 1. AML cell lines are obtained from human peripheral blood or bone marrow. After blood/marrow aspiration, the sample is mixed with PBS in a 1:1 or 1:2 ratio and transferred to centrifuge tubes containing gradient buffer. 2. The obtained cell suspension is centrifugated in the density gradient buffer to obtain a buffy coat consisting of mononuclear cells. 3. The next step is isolated cell counting and suspension of the cells in fresh medium and transferring them to the culture flask, plate, or dish. 4. Continuous culture of the isolated cells in a selected medium supplemented with or without fetal bovine/calf serum (FBS/FCS), growth factors, and cytokines. 5. To verify the malignant origin of these cells, they are inoculated to the immunodeficient mice. The figure was created using templates from Servier Medical Art, licensed under a Creative Commons Attribution 3.0 Unported License (http://smart.servier.com/, accessed on 27 December 2022).
See this image and copyright information in PMC

References

    1. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., Sultan C. Proposals for the Classification of the Acute Leukaemias. French-American-British (FAB) Co-Operative Group. Br. J. Haematol. 1976;33:451–458. doi: 10.1111/j.1365-2141.1976.tb03563.x. - DOI - PubMed
    1. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., Sultan C. Proposed Revised Criteria for the Classification of Acute Myeloid Leukemia. A Report of the French-American-British Cooperative Group. Ann. Intern. Med. 1985;103:620–625. doi: 10.7326/0003-4819-103-4-620. - DOI - PubMed
    1. Naeim F., Rao P.N. Chapter 11—Acute Myeloid Leukemia. In: Naeim F., Rao P.N., Grody W.W., editors. Hematopathology. Academic Press; Oxford, UK: 2008. pp. 207–255. - DOI
    1. Ladines-Castro W., Barragán-Ibañez G., Luna-Pérez M.A., Santoyo-Sánchez A., Collazo-Jaloma J., Mendoza-García E., Ramos-Peñafiel C.O. Morphology of Leukaemias. Rev. Médica Hosp. Gen. México. 2016;79:107–113. doi: 10.1016/j.hgmx.2015.06.007. - DOI
    1. Khoury J.D., Solary E., Abla O., Akkari Y., Alaggio R., Apperley J.F., Bejar R., Berti E., Busque L., Chan J.K.C., et al. The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–1719. doi: 10.1038/s41375-022-01613-1. - DOI - PMC - PubMed

LinkOut - more resources